‡a
Author's Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
‡a
prospectivesubgroupanalysesoftherandomized1150002sprintstudylenalidomideversusinvestigatorschoiceinrelapsedorrefractorymantlecelllymphoma
‡A
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
‡9
1